# Does Ohio Medicaid Cover Wegovy or Zepbound? What the Unified Drug List Says By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-11-06 Canonical page: https://glpwatchdog.org/research/ohio-medicaid-glp1-coverage > Ohio's rule bars obesity drugs, yet its October 2026 Unified Preferred Drug List carries a small Wegovy class for heart disease and MASH. Renewal needs 5% weight loss. Zepbound is absent, and Ozempic and Mounjaro sit behind older diabetes drugs. ## Key points - An Ohio rule names drugs for the treatment of obesity as non-covered. - The October 2026 list carries Wegovy for heart risk and MASH, and Zepbound nowhere. - People with type 1 or type 2 diabetes cannot use the heart route. - Renewal for heart risk asks for 5% weight loss and claims covering 80% of days. - Ozempic and Mounjaro need 120 days on three preferred drugs first. No, not for weight loss. Ohio’s Medicaid rule lists drugs for the treatment of obesity as non-covered, and Zepbound does not appear on the state’s October 2026 drug list at all.[1][2] Wegovy is covered for two other uses, reducing heart risk in people without diabetes and treating the liver disease MASH.[1] > **About this article.** This page reads Ohio’s Unified Preferred Drug List effective October 1, 2026, the state rule on covered drugs and the committee minutes behind the Wegovy class. For the national picture, see [why Medicaid treats Ozempic and Wegovy differently](https://glpwatchdog.org/research/does-medicaid-cover-ozempic-and-wegovy). ## Why doesn't Ohio Medicaid cover GLP-1s for weight loss? Federal Medicaid law does not require states to cover weight-loss drugs, and Ohio left them out in its administrative code, which lists obesity drugs first among its non-covered categories.[2][10] A notice from Ohio Medicaid’s pharmacy benefit manager, effective December 8, 2025, applied the same line to the preferred diabetes GLP-1s, requiring a type 2 diabetes diagnosis and saying coverage is not available for uses such as prediabetes or weight loss.[4] Ohio’s drug list is unified, so the answer does not change by plan: the same document covers fee-for-service and every managed care plan.[1] Changing from one Ohio Medicaid plan to another will not open up a weight-loss route. *Ohio Medicaid GLP-1 routes on the Unified Preferred Drug List effective October 1, 2026.* | Drug and use | Status | Main conditions | | --- | --- | --- | | Wegovy, Zepbound, Saxenda or Foundayo for weight loss | Not covered[2] | None of these drugs is listed for that use[1] | | Wegovy injection or tablet, heart risk | Preferred, prior authorization[1] | Age 18+, BMI 27+, past heart attack or stroke or symptomatic artery disease, no diabetes | | Wegovy injection or tablet, MASH | Preferred, prior authorization[1] | Age 18+, noncirrhotic, F2 or F3 confirmed; renewal needs liver improvement | | Zepbound for sleep apnea | Not listed[1] | No class or criteria on the list | | Trulicity, Victoza, liraglutide, Byetta, exenatide for type 2 diabetes | Preferred[1] | Type 2 diabetes diagnosis[4] | | Ozempic, Mounjaro, Rybelsus for type 2 diabetes | Non-preferred, prior authorization[1] | 120 days on three preferred drugs; Mounjaro also after Ozempic | ## Does Ohio Medicaid cover Wegovy for heart disease? Yes. In January 2026, the department proposed and its pharmacy committee backed a new category called Metabolic Modifiers, with a subcategory for GLP-1s used for non-obesity indications, and Wegovy is its only drug.[1][3] The list excludes the 7.2 mg injection.[1] A request needs all of the following:[1] - An adult with a BMI at or above 27. - Chart notes showing a past heart attack, a past stroke, or symptomatic peripheral artery disease, meaning claudication with an ankle-brachial index below 0.85 at rest, a revascularization procedure or an amputation from atherosclerotic disease. - No type 1 or type 2 diabetes. Those patients are sent to the diabetes class. - Standard heart treatment documented, such as an antiplatelet drug, a lipid-lowering drug and a blood pressure drug, or the reason a person cannot take them. - No other GLP-1 at the same time. Approval lasts 180 days.[1] The diabetes exclusion is sharper than the label, which sets no such bar for the heart use, and it is what makes the class odd: a person with diabetes and a past heart attack has to go through the diabetes route, starting with older preferred drugs.[1][8] ## Why does renewal require 5% weight loss? Ohio’s renewal for the heart route asks for chart notes showing at least 5% weight loss from baseline, along with claims showing at least 80% of days covered.[1] The state does not explain the rule in the list. It sits awkwardly with the trial evidence: a prespecified analysis of 17,604 people in SELECT concluded that semaglutide’s heart protection was independent of baseline adiposity and weight loss.[7] That analysis was funded by the drug’s maker. Our piece on [what weight loss did and did not predict](https://glpwatchdog.org/research/losing-weight-predicted-more-heart-attacks) walks through the numbers. In practice, someone who stays on Wegovy for 180 days, takes the standard heart medicines and loses 4% could face a denial. If that happens, ask the prescriber to put the full cardiovascular record into the renewal, and start planning before the approval ends. ## Does Ohio Medicaid cover Wegovy for MASH? Yes, for adults with noncirrhotic MASH and stage F2 or F3 fibrosis, confirmed by a liver biopsy in the prior 24 months or by two noninvasive measures, such as a Fibrosis-4 index or Enhanced Liver Fibrosis blood test plus a liver stiffness scan.[1] The prescriber attests to diet, activity and optimized care for related heart conditions, and the person cannot be on another MASH drug such as resmetirom or another GLP-1.[1] Renewal is demanding: 5% weight loss, 80% of days covered, and resolution of steatohepatitis without worse fibrosis, or one stage of fibrosis improvement without worse steatohepatitis.[1] For background on the evidence, see [GLP-1s and fatty liver](https://glpwatchdog.org/research/glp1-and-fatty-liver-mash). ## Does Ohio Medicaid cover Zepbound for sleep apnea? Not on the current list. Zepbound appears nowhere in the October 2026 Unified Preferred Drug List, and the Metabolic Modifier class names only Wegovy.[1] Sleep apnea is a labeled use of Zepbound in adults with obesity, and some programs and insurers pay for it, but the Ohio list has no such route.[9] A prescriber can ask the plan how an off-list request would be handled, though we found no Ohio criteria for one. ## Are Ozempic and Mounjaro covered for diabetes in Ohio? Yes, but they are not first in line. The preferred GLP-1s are Trulicity, Victoza, liraglutide, Byetta and exenatide, and a claim requires a type 2 diabetes diagnosis.[1][4] Ozempic, Mounjaro and Rybelsus are non-preferred, with detailed criteria:[1] 1. At least 120 days of inadequate response with three preferred drugs in the category, including two used together and doses taken to the maximum tolerated. 2. A current A1C from the past six months, and a patient-specific goal if the target is below 7%. 3. For anyone who stopped a GLP-1 because of stomach problems, 30 days of tried fixes: dietary changes, antiemetic prescriptions and a dose adjustment. 4. For Mounjaro, an A1C above 7% and 120 days on Ozempic, or a documented reason Ozempic cannot be used. Approval runs for 365 days, and renewal needs a recent A1C showing improvement from baseline.[1] Someone already taking Mounjaro should check the current status with the plan before a renewal date. ## How do you appeal an Ohio Medicaid denial? - **Plan appeal.** Managed care members have 60 calendar days from the notice.[6] - **State hearing.** You then have 90 calendar days after the plan’s appeal decision is mailed.[5] Fee-for-service members also get 90 days from a notice of action.[5] Because obesity drugs are excluded by rule, an appeal asking for weight-loss coverage is unlikely to win. Appeals have more room when the record was incomplete for heart disease, MASH or a non-preferred diabetes drug. [Our guide to prior authorization and appeals](https://glpwatchdog.org/research/glp1-prior-authorization-and-appeals) shows what to send, and [the state Medicaid checker](https://glpwatchdog.org/tools/state-medicaid-glp1-checker) compares other states. ## What are the options without Ohio Medicaid coverage? Self-pay is the usual route, and Lilly’s savings card excludes government programs.[11] Prices in the figures we track are $349 a month for most Wegovy pen doses from Novo Nordisk, and from $299 at the starting dose up to $449 at higher doses for Lilly’s Zepbound KwikPen or vial.[11][12] Check whether each offer accepts Medicaid members. The guide to the [lowest GLP-1 prices without insurance](https://glpwatchdog.org/research/cheapest-glp1-without-insurance) compares them, and our national overview of [Medicaid coverage for Zepbound](https://glpwatchdog.org/research/does-medicaid-cover-zepbound) shows how Ohio compares. ## Frequently asked questions ### Is Wegovy covered for weight loss by Ohio Medicaid? No. Ohio's rule lists drugs for the treatment of obesity as non-covered. Wegovy is on the October 2026 list only for reducing heart risk and for the liver disease MASH, with prior authorization, and the heart route is not authorized for people with type 1 or type 2 diabetes. ### Does Ohio Medicaid cover Zepbound? Zepbound does not appear on the October 2026 Unified Preferred Drug List, for weight loss or for sleep apnea. Mounjaro, which contains the same drug, is listed as non-preferred for type 2 diabetes. ### Does Ohio Medicaid cover Ozempic? Yes, for type 2 diabetes, as a non-preferred drug with prior authorization. The list asks for at least 120 days of inadequate response with three preferred drugs. Trulicity and Victoza are among the preferred options. Prediabetes and weight loss do not qualify. ### Do all Ohio Medicaid plans follow the same drug list? Yes. The Unified Preferred Drug List applies to Medicaid fee-for-service and managed care plans, so switching plans will not change whether a GLP-1 is covered. ### How long does Ohio Medicaid approve Wegovy? 180 days at a time. Renewal for heart risk needs a 5% drop from starting weight and claims covering 80% of days. Renewal for MASH also needs an improvement in the liver disease. ## References 1. Ohio Department of Medicaid Unified Preferred Drug List: Medicaid Fee-for-Service and Managed Care Plans, effective October 1, 2026. medicaid.ohio.gov. 2026. https://dam.assets.ohio.gov/image/upload/medicaid.ohio.gov/PHM/unified-pdl/Unified_Preferred_Drug_List_Effective_October_2026_V3.pdf 2. Ohio Department of Medicaid Ohio Administrative Code 5160-9-03: Pharmacy services: covered drugs and associated limitations. codes.ohio.gov. 2024. https://codes.ohio.gov/ohio-administrative-code/rule-5160-9-03 3. Ohio Department of Medicaid Pharmacy & Therapeutics Committee meeting minutes, January 7, 2026 (draft). medicaid.ohio.gov. 2026. https://dam.assets.ohio.gov/image/upload/medicaid.ohio.gov/PHM/p-t-committee/20260107_PT_Meeting_Minutes_DRAFT_FINAL.pdf 4. Ohio Department of Medicaid Ohio Medicaid single pharmacy benefit manager news notice on GLP-1 receptor agonists, effective December 8, 2025. spbm.medicaid.ohio.gov. 2025. https://spbm.medicaid.ohio.gov/ 5. Ohio Department of Job and Family Services Ohio Administrative Code 5101:6-3-02: State hearings: requesting a state hearing. codes.ohio.gov. 2026. https://codes.ohio.gov/ohio-administrative-code/rule-5101:6-3-02 6. Ohio Department of Medicaid Ohio Administrative Code 5160-26-08.4: Managed care: appeal and grievance system. codes.ohio.gov. 2026. https://codes.ohio.gov/ohio-administrative-code/rule-5160-26-08.4 7. Deanfield J, et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet. 2025. PMID: 41138739. DOI: 10.1016/S0140-6736(25)01375-3. https://pubmed.ncbi.nlm.nih.gov/41138739/ 8. Novo Nordisk WEGOVY (semaglutide): prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b 9. Eli Lilly and Company ZEPBOUND (tirzepatide) injection: prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b 10. United States Code 42 U.S.C. §1396r-8: Payment for covered outpatient drugs. Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/uscode/text/42/1396r-8 11. Eli Lilly and Company Zepbound savings and self-pay options, with card terms. zepbound.lilly.com. 2026. https://zepbound.lilly.com/savings 12. Novo Nordisk Wegovy savings offer. novocare.com. 2026. https://www.novocare.com/obesity/products/wegovy/savings-offer.html --- Cite as: GLP Watchdog, Nora Bissett, "Does Ohio Medicaid Cover Wegovy or Zepbound? What the Unified Drug List Says", published 2026-11-06. https://glpwatchdog.org/research/ohio-medicaid-glp1-coverage Canonical HTML page: https://glpwatchdog.org/research/ohio-medicaid-glp1-coverage Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.